1. Programs
  2. In Development Programs

In Development Programs

We undertake new program development with a goal of scaling only the most cost-effective, evidence-based interventions.

Our Accelerator process is designed to identify as many foreseeable challenges to scaling — and accompanying solutions — as possible, and to hold us accountable for prioritizing only those interventions that best align with our organizational values and with our core principles of evidence, cost-effectiveness, and scale. In this way, we maximize the impact of our and our donors’ investments, enabling us to reduce poverty for millions of people.

Here are a few in-development programs that are currently in our Accelerator pipeline.

HPV Vaccine in School Age Girls

Accelerator Stage 5

Scoped in Kenya and India

We’re looking at fighting cervical cancer by improving global access to the HPV vaccine. In 2020, there were an estimated 604,000 new cases of cervical cancer and 342,000 related deaths – with 90% being in low- and middle-income countries. The HPV vaccine is 99% effective at preventing the two most common strains of HPV when given to adolescent girls, significantly reducing their risk of cervical cancer. We’re scoping this intervention to see if we find school-based delivery to be viable for cost-effective implementation at scale.

Multivitamin Supplementation for Pregnant Women (MMS)

Accelerator Stage 4

Scoped in India, Nigeria, Uganda, Malawi, and Pakistan

We’re testing an intervention that helps pregnant women overcome micronutrient deficiencies. Micronutrient deficiencies are highly prevalent among pregnant women in low- and middle- income countries and can cause poor pregnancy and birth outcomes. Evidence shows that multiple micronutrient supplementation (MMS) can be an effective, low-cost solution if taken regularly during pregnancy — reducing low birthweight by 21%, stillbirths by 9% and small for gestational age (SGA) by 10%. MMS has yet to be introduced in most countries at scale, so we’re looking at the feasibility of scaling MMS delivery cost-effectively through prenatal care systems.